Nama's AI scorecard currently rates Integer Hold (4.4 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is ITGR's P/E ratio?

Integer trades at a trailing price-to-earnings ratio of 21.4.

When does ITGR report earnings?

Integer's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $1.79.

What is the ITGR price target?

The median analyst price target from 4 analysts is $127.00, with a range of $127.00 – $127.00.

Is ITGR Shariah compliant?

Nama's AAOIFI-style screen reads Integer as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Integer (ITGR)

Healthcare · Medical Devices · NYSE

Integer (ITGR) is a Healthcare company in the Medical Devices industry. It has a market capitalization of $4.30B, a trailing price-to-earnings ratio of 21.4 and a free-cash-flow yield of 2.3%. Over the most recent reported fiscal year, revenue grew 8.0% and free cash flow per share grew 5.4%. Nama's AI scorecard rates it Hold, 4.4 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Hold · 4.4/10

The sections balance. As of Nov 7, 2026.

Momentum

Leading · +90.0% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-13.5%

How far the last close sits under the highest price of the past five years.

Market cap	$4.30B
Trailing P/E	21.4
Price / book	2.5
Price / sales	2.4
FCF yield	2.3%
Dividend yield	—
Gross margin	25.7%
Operating margin	10.9%
Net margin	7.0%
Revenue growth (YoY)	+8.0%
Revenue growth (3-yr annual)	+11.7%
EPS growth (YoY)	+20.9%
FCF/share growth (YoY)	+5.4%
Beta	0.6
Exchange	NYSE
Sector	Healthcare
Industry	Medical Devices

ITGR earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate $1.79). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 29, 2026	$1.34	$1.68	-20.2%	$449.66M
Q2 2026	Aug 3, 2026	$1.60	$1.38	+15.9%	$464.11M
Q1 2026	Apr 30, 2026	$1.20	$1.19	+0.8%	$439.58M
Q4 2025	Feb 19, 2026	$1.76	$1.70	+3.5%	$472.06M

ITGR analyst price target

Median target $127.00 from 4 analysts, ranging $127.00 – $127.00.

Medical Devices peers

Ticker	Company	Market cap	P/E
ABT	Abbott Laboratories	$190.39B	20.4
MDT	Medtronic	$130.22B	17.8
SYK	Stryker	$124.06B	22.8
BSX	Boston Scientific	$61.96B	13.4
EW	Edwards Lifesciences	$58.73B	34.7
GEHC	GE HealthCare Technologies	$37.25B	16.8
PHG	Koninklijke Philips	$29.67B	15.2
DXCM	DexCom	$29.62B	29.7

Explore live ITGR data on Nama Insights →

ITGR FAQ

Is ITGR a buy?: Nama's AI scorecard currently rates Integer Hold (4.4 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is ITGR's P/E ratio?: Integer trades at a trailing price-to-earnings ratio of 21.4.
When does ITGR report earnings?: Integer's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $1.79.
What is the ITGR price target?: The median analyst price target from 4 analysts is $127.00, with a range of $127.00 – $127.00.
Is ITGR Shariah compliant?: Nama's AAOIFI-style screen reads Integer as Not Shariah Compliant. At least one of the three ratios or the industry test failed.